Review
Management strategies for chronic liver disease-related thrombocytopenia
Qian Jiandan, Yao Tiantian, Wang Yan, Wang Guiqiang
Published 2021-09-20
Cite as Chin J Hepatol, 2021, 29(9): 896-899. DOI: 10.3760/cma.j.cn501113-20200609-00304
Abstract
Chronic liver disease causes bleeding and coagulation system abnormalities through a variety of mechanisms. Thrombocytopenia is a common complication of chronic liver disease. Patients with chronic liver disease, especially liver cirrhosis, often face more invasive examinations or surgeries, which brings great challenges to clinical diagnosis and treatment. Traditional platelet transfusion is the main clinical intervention. With the approval of thrombopoietin receptor agonists, the current management standards for chronic liver disease-related thrombocytopenia may face changes. This article reviews the current main non-pharmacological and pharmacological interventions for chronic liver disease-related thrombocytopenia, and put forwards the corresponding clinical management improvement strategies based on the efficacy and limitations of these interventions.
Key words:
Chronic liver disease; Thrombocytopenia; Thrombopoietin receptor agonists
Contributor Information
Qian Jiandan
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China
Yao Tiantian
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China
Wang Yan
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China
Wang Guiqiang
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China